Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs.
Biomed’s team has discovered a new family of drugs for the treatment of Alzheimer’s disease, Major Depressive Disorder (MDD), diabetes obesity and rare diseases including Rett Syndrome and Fragile X.
Biomed Industries, Inc. is the parent company of Biomed Pharmaceuticals, Inc., NeuroActiva, Inc., and BiomedAI, LLC., Biomed Digital, LLC. and MedAware Systems, Inc.
Biomed Pharmaceuticals™ Inc. was the developer of Artemether, which was approved by the FDA along with lumefantrine for the treatment of malaria.
NeuroActiva™ is the early developer of NA-831 which is ready for Phase 3 clinical trials for the prevention and treatment of Alzheimer's disease and other neurodegenerative diseases.
MedAware Systems, Inc. is a next generation medical data and analytics company. Through its Artificial Intelligence applications the Company provides unprecedented business intelligence for drug development, support for regulatory filings, competitive analysis, and marketing messaging.
Our Story
The management team is led by Lloyd L. Tran, the company Chairman. Lloyd has been a research scientist, with 25 years of experience in drug discovery working for major pharmaceutical companies including Monsanto and Pfizer.
Lloyd was the drug developer of Artemether for the treatment of malaria in early 1990’s in collaboration with a Chinese research team. He coordinated the clinical trials of Artemether gel capsule with World Health Organization (WHO) and Walter Reed Army Institute of Research (WRAIR) that lead to its approval in over 80 countries worldwide, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration.
After the success of Artemether, Lloyd focused on neurodegenerative diseases when his father developed symptoms of Alzheimer’s disease. He filed his first patent application in 2001 on neurogenesis for Alzheimer’s disease.
In Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive impairment. NA-831 facilitates neurogenesis, restoring memory loss and cognitive functions.
The Phase 2A clinical data of NA-831 has shown a proof of safety and efficacy for patients with mild and moderate Alzheimer's disease. Biomed plans to conduct a Phase 2B and Phase 3 for the treatment and prevention of Alzheimer's disease.
In addition, Biomed's team has developed a family of drugs that can be used for the treatment of Major Depressive Disorder (MDD), diabetes obesity and rare diseases including Rett Syndrome and Fragile X.
For further information about our products, please contact us
